TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of NIV on QoL and Exercise Capacity in a COPD Exercise Rehabilitation Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of COPD III+IV~* Age \>18 years~* Former NIV treatment for at least 6 weeks with a positive end-expiratory pressure of at least 4 cmH2O and a pressure support of 8 cmH2O or higher~Exclusion Criteria:~* Pulmonary Exacerbation requiring antibiotic treatment or hospitalization during the last 6 weeks~* non-pulmonary Exercise impairment (amputation, severe heart disease, etc)~* any disease that precludes exercise training~* inability to understand the patient information~* substance abuse~* oxygen requirement of more than 6l O2/min during exercise

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: NO_INTERVENTION): This arm will perform the pulmonary rehabilitation as specified with no respiratory assistance.
- Intervention Arm (Type: ACTIVE_COMPARATOR): This arm will conduct the pulmonary rehabilitation program with BiLevel Noninvasive Ventilation assistance from a ResMed ventilator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. GOLD criteria for moderate COPD (post-bronchodilator)~   * FEV1/FVC \< 70%~  * 50% ≤ FEV1 \< 80% predicted~  * With or without symptoms~2. Willing to undergo the treatment protocol with signed informed consent~Exclusion Criteria:~1. Exacerbation within 1 month prior to run-in period~2. Significant hypoxemia and/or desaturation at rest and during exercise.~3. Significant cardiac, renal, or other systemic disease~4. History of adverse reaction to any of the two test drugs (tiotropium and procaterol)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* These criteria depend on the subgroup belongs to the patient.~* Signed consent~* Membership of a social security system~Exclusion Criteria:~* Whatever the patient group or control:~* Processing immunosuppressive.~* Processing by a monoclonal antibody.~* Previous treatment with an immunosuppressant for a significant period of time (more than 6 months of oral treatment, more than 6 cycles of cyclophosphamide over 3 cures mitoxantrone).~* Carcinomatous pathology known evolving.~* People under guardianship.~* Pregnant women.~* Patients not motivated to study. Known patients with anemia (hemoglobin \<10g/100ml)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Relapsing Multiple Sclerosis- group 1 (Type: OTHER): Definite multiple sclerosis according to the McDonald criteria, relapsing Patient innocent of thorough treatment or treatment immunomodulator stopped for at least 6 months.
- Relapsing Multiple Sclerosis- group 2 (Type: OTHER): Multiple sclerosis defined according to the criteria of McDonald, relapsing Patient under treatment immunomodulator for at least 6 months.
- secondary progressive multiple sclerosis- Group 3 (Type: OTHER): Multiple sclerosis defined according to the criteria of McDonald, secondary progressive multiple sclerosis
- primary progressive multiple sclerosis- group 4 (Type: OTHER): Multiple sclerosis defined according to the criteria of McDonald, primary progressive multiple sclerosis
- control 1 (Type: OTHER): healthy volunteers
- Control 2 (Type: OTHER): Patients with central or peripheral neurological non-inflammatory, non-autoimmune.
- Control 3 (Type: OTHER): Patients having an autoimmune pathology

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Monocenter, Cross-sectional Study to Compare Different Type of Cognitive Impairment in Multiple Sclerosis Patients and Cerebrospinal Fluid Biomarkers (Beta Amyloid, Total Tau Protein and Tau-phosphorylated Protein).

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Groups 1 and 2 -patients MS - EDSS\<7~Group 3- patients with first clinical inflammatory symptom~Exclusion Criteria:~* Pregnant or not taking contraceptive~* Contraindication for lumbar puncture~* Contraindication for NMR

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- group 1 (Type: OTHER): MS with cortical cognitive troubles
- group 2 (Type: OTHER): MS with subcortical cognitive troubles
- group 3 (Type: OTHER): MS in the early stage of the disease when cognitive troubles are absent or inconspicuous

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ocular Pressure in Steroid-treated Dermatology Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* patients on whom corticosteroid treatment is being introduced for a duration of at least 12 weeks~Exclusion Criteria:~* pregnant women~* patients already under glaucoma treatment~* patients unable to give informed written consent or those unable to cooperate fully with the assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Potent topical steroid-treated (Type: None): Patients treated with potent topical steroids
- Superpotent topical steroid-treated (Type: None): Patients treated with superpotent topical steroids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Less Trendelenburg Make a Difference in Robotic Assisted Gynecological Procedures?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all women at Lutheran General Hospital undergoing robotic-assisted benign gynecologic procedures and who agree to participate in the study.~* Women who are 18 years or older on the day of surgery.~* Patients with any co-morbidity or prior surgery, as long as they are cleared by their surgeon and anesthesia to undergo robotic-assisted surgery.~Exclusion Criteria:~* pregnant women~* Anyone who is less than 18 years old on the day of surgery.~* Anyone who does not have the capacity to make independent medical decisions.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: OTHER): Steep Trendelenburg
- Group B (Type: EXPERIMENTAL): Decreased Trendelenburg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient and/or their parent/legal guardian is willing and able to provide signed informed consent. If the patient is below the age of consent per local guidelines, he is willing to provide assent, if deemed able to do so.~* The patient must have a confirmed diagnosis of Fabry disease as documented by leukocyte α-galactosidase A (αGAL) of \<4 nmol/hr/mg leukocyte (preferred assay; results from a central laboratory). If the leukocyte αGAL activity assay is difficult to obtain, the patient may be enrolled based on documented plasma αGAL \<1.5 nmol/hr/mL (results from a central laboratory), with the agreement of the Genzyme Medical Monitor.~Exclusion Criteria:~* Patient has received prior treatment with enzyme replacement therapy (ERT) or oral pharmacological chaperone therapy for Fabry disease.~* Patient has received an investigational drug within 30 days of the screening visit.~* Patient is receiving any of the following medications and is clinically unable or unwilling to temporarily discontinue treatment with these medications for the indicated washout period prior to the renal function assessments until completion of these assessments:~  * Angiotensin converting enzyme inhibitors or angiotensin receptor blockers (6 week washout);~ * Non-steroidal anti-inflammatory drugs (3 day washout).~ * NOTE: Patients who are on chronic dialysis or have had a kidney transplant will not be required to discontinue the above medications because renal function assessments will not be performed in these patients.~* Patient has any contraindication mentioned in the labeling of iohexol. NOTE: patients with an eGFR \<30 mL/min/1.73m\^2 and patients who are on chronic dialysis or have had a kidney transplant may be enrolled irrespective of any contraindication to iohexol because iGFR will not be measured in these patients.~* Patient has any medical condition or extenuating circumstance which, in the opinion of the Investigator, could interfere with the patient's ability to complete all study procedures, or with the interpretation of study results (e.g., diabetes mellitus).~* The patient and/or their parent or legal guardian, in the opinion of the Investigator, is unable to adhere to the requirements of the study.

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Glomerular Filtration Rate by Plasma Iohexol Clearance (iGFR) (Type: OTHER): Evaluations of renal and cardiac function

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All preterm infants of gestational age less or equal to 28 weeks completed gestational age and 10 to 15 days of postnatal age admitted to our regional NICU

- Gender: ALL
- Minimum Age: 10 Days
- Maximum Age: 15 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Single-Laser PVI: Single-encirclement Laserballoon Ablation for Pulmonary Veins Isolation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To participate in this clinical subject, the subject must meet all of the following inclusion criteria:~* Age between 18 and 85 years~* Paroxysmal or persistent AF~* Patients AF who have indications for the first time ablation procedure according to the ESC / EHRA recommendations (European Society of Cardiology / European Heart Rhythm Association).~* Ability to provide written informed consent for study participation and be willing and able to comply with the study evaluations and follow up schedule~Exclusion Criteria:~Subjects are not eligible for clinical study participation if they meet any of the following exclusion criteria:~* Previous AF ablation procedures~* Secondary AF due to other causes~* Hyperthyroidism~* Left ventricular ejection fraction \<30%~* NYHA class IV~* Left atrium area \> 35 cm2~* Severe disease of cardiac valves~* Contraindication to anticoagulant therapy~* Presence of thrombus in the left atrium~* Myocardial infarction or unstable angina or recent coronary artery bypass (\<6 months)~* Thoracic surgery for congenital, valvular or aortic disease~* History of cerebrovascular events~* Pregnancy~* Significant comorbidity, such as cancer, severe kidney failure requiring dialysis, severe obstructive pulmonary disease, cirrhosis, with a life expectancy of less than 2 years~* Contraindications are present as indicated in the instructions for use of the devices used

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals ≥18 years of age will be enrolled.~* Patients must have histologic confirmation of a solid tumor malignancy that will be treated with a regimen that contains full-dose oxaliplatin.~* Patients may be receiving treatment in the neoadjuvant, adjuvant or metastatic setting.~* Patients must be treatment-naïve to platinum-agents at the time of enrollment. Prior treatment with non-platinum agents is permitted.~Exclusion Criteria:~* Any active intraoral infection, including yeast infection (thrush) or active oral herpes simplex virus at the time of enrollment.~* Patients may not have dentures.~* Patients may not have a disorder that may result in altered taste sensation at baseline. This includes but is not limited to: persistent dry mouth.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): will be treated with consistent exposure to oral ice
- Arm B (Type: ACTIVE_COMPARATOR): Will not be treated with consistent exposure to oral ice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Weighted Vaginal Cones Versus Biofeedback in the Treatment of Urodynamic Stress Incontinence: a Randomized Trial.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females, between the ages of 18-65 years, will be entered into this study. Additional inclusion criteria are a history of urinary stress incontinence and multichannel cystometry confirming the presence of genuine stress incontinence (GSI).~Exclusion Criteria:~* urodynamic identification detrusor instability~* active (untreated or resistant) urinary tract infection~* any other disease that is felt by the investigators to potentially interfere with participation (e.g. arthritis limiting dexterity and thus interfering with the insertion and removal of vaginal cones)~* previous treatment with pelvic floor physiotherapy with biofeedback or functional electric stimulation for urinary incontinence~* previous use of weighted vaginal cones~* previous anti-incontinence surgery~* significant pelvic organ prolapse or those with abnormal vaginal anatomy (the Pelvic Organ Prolapse Quantification (POP-Q) system of scoring for prolapse will be used, Grade \> III)~* use of concomitant treatments during the trial or the start of new medications that may alter continence mechanism~* inability to understand instructions in French or English or provide informed consent (e.g., psychiatric disease).~* pregnancy (which may alter pelvic anatomy may over the course of the study and thus make evaluation of treatment methods impossible)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- a (Type: EXPERIMENTAL): Weighted vaginal cones used to perform pelvic floor exercises
- b (Type: ACTIVE_COMPARATOR): Biofeedback

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of grade 1-3 follicular lymphoma with persistent, relapsed, or refractory disease to at least one prior regimen.~* No prior bortezomib therapy.~* Voluntary written informed consent.~* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control.~* Male subject agrees to use an acceptable method for contraception for the duration of the study therapy.~* 18 years of age or older.~* aspartate aminotransferase (AST),alanine aminotransferase (ALT), total bilirubin \< 3 times the upper limit of normal unless documented by the treating physician to be secondary to underlying lymphoma.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.~Exclusion Criteria:~* Platelet count of \< 50,000 within 14 days before enrollment unless documented by the treating physician to be due to the disease.~* Absolute neutrophil count of \< 1000 within 14 days before enrollment unless documented by the treating physician to be due to disease.~* Estimated or measured creatinine clearance of less than 30 ml/min within 14 days before enrollment.~* ≥Grade 2 peripheral neuropathy within 14 days before enrollment.~* Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.~* Patient has hypersensitivity to boron, mannitol or any drug included in the current protocol.~* Female subject is pregnant or lactating.~* Received other investigational drugs for this disease within 14 days of enrollment~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study.~* Known HIV+ status.~* Cardiac ejection fraction less than 35% at study entry measured by echocardiogram, Multigated Acquisition (MUGA) or cardiac MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VR-FND (Type: EXPERIMENTAL): Bortezomib (VELCADER) 1.6 mg/m2 IV days 1 and 8 Rituximab 375 mg/m2 IV on day 1 Fludarabine 25 mg/m2 IV on days 1,2,3 Mitoxantrone 10 mg/m2 IV on day 2 Dexamethasone 20 mg orally on days 1,2,3,4,5 On day 1 the sequence of drug administration will be Bortezomib followed by Fludarabine followed by Rituximab.~Each cycle will be repeated every 28 days for 8 cycles maximum.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cortical Biomarkers of Hand Function and Recovery After Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Normal or corrected to normal vision~* Hand impairment due to spinal cord injury or stroke~* Weakness of fingers~* One year after stroke or spinal cord injury~* Some proprioception (can feel when finger is moved, without seeing)~* Minimal spasticity~Exclusion Criteria:~* Implanted metal with is unsafe for MRI~* Pregnant or expecting to become pregnant~* History of hand surgery which is under evaluation~* Cognitive or language issues that would interfere with following directions~* Other neurological disorder that would affect movement~* History of seizure or epilepsy~* Body weight \> 300 pounds

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Hand impairment due to stroke or spinal cord injury (Type: EXPERIMENTAL): Individuals who have experienced a sub-cortical stroke or a cervical spinal cord injury resulting in loss of hand function.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues